ID   TMH-1
AC   CVCL_3219
DR   BioSample; SAMN03151799
DR   BioSample; SAMN03472499
DR   cancercelllines; CVCL_3219
DR   Cell_Model_Passport; SIDM00601
DR   JCRB; JCRB1078
DR   JCRB; NIHS0267
DR   Wikidata; Q54972696
RX   PubMed=11686581;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a IHH-4 derivative (PubMed=20143388). Originally thought to originate from a 79 year old female patient with a thyroid gland anaplastic carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00349.
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Trp592Ter (c.1776G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 14281; CRLF2; Simple; p.Trp255Ter (c.765G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Arg1312Ter (c.3934C>T); ClinVar=VCV000545969; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp11Glu (c.33C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Discontinued: JCRB; NIHS0267; true.
CC   Derived from site: Metastatic; Left cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10,13
ST   D16S539: 9,11
ST   D5S818: 9,13
ST   D7S820: 9,10
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 16,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2960 ! IHH-4
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=11686581; DOI=10.1016/S0753-3322(01)00087-7;
RA   Sekiguchi M., Shiroko Y., Arai T., Kishino T., Sugawara I.,
RA   Kusakabe T., Suzuki T., Yamashita T., Obara T., Ito K., Hasumi K.;
RT   "Biological characteristics and chemosensitivity profile of four human
RT   anaplastic thyroid carcinoma cell lines.";
RL   Biomed. Pharmacother. 55:466-474(2001).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//